Key Segments
By Application
-
Plaque Psoriasis
-
Psoriatic Arthritis (PsA)
-
Others
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Turkey
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g., Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: Tremfya is well-positioned as a first-in-class IL-23 inhibitor with subcutaneous and IV dosing flexibility, making it a preferred choice for long-term disease control.
Ans: Major competitors include AbbVie (Skyrizi), Eli Lilly (Taltz), Novartis (Cosentyx), Amgen, and UCB, which offer similar biologics in the IL-23, IL-17, and TNF spaces.
Ans: North America dominates the Tremfya market with over 85% share in 2024, followed by Europe, due to early approvals, high diagnosis rates, and broad insurance coverage.
Ans: Key growth drivers include rising prevalence of autoimmune conditions, increasing demand for IL-23 inhibitors, favorable clinical outcomes, and strong regulatory support for label expansion.
Ans: Over the past five years, the Tremfya market has grown steadily due to expanded indications, wider geographic access, and its strong safety-efficacy profile compared to older biologics.
Get in touch
